Analysis Tools
mortality/aging
|
• showed increased mortality at about 13 months of age and only about 80% survived at 15 months
|
immune system
|
• 42% exhibited abnormal B cell expansions involving predominately the spleen but also the lymph nodes compared to 11% in wild-type and displayed features of benign lymphoproliferative disease
|
|
• about a 30% reduction in the number of total plasmacytoid cells (B220+/- CD138+), mainly due to a decrease in post-CSR plasma cells (IgM-IgD-), while IgM+IgD+ plasma cells were normal
|
|
• 17% displayed a complete effacement of the splenic lymphoid architecture due to the proliferation of large lymphoid cells
|
|
• 17% exhibited a modest splenomegaly at 6 months of age
|
|
• partial effacement of the follicular architecture with the appearance of blast cells
|
|
• nonimmunized mutant mice displayed an increased number of germinal centers, comparable to that observed upon immunization in wild-type mice, and the increase in the number of germinal centers and an increase in the total germinal center area persisted after immunization
|
|
• expanded white pulp composed predominately of B cells, but also included disorganized accumulations of other cell types such as T cells and dendritic cells
|
|
• displayed a small (20-50%) reduction in total serum immunoglobulin levels of all subclasses, except for IgM, both under basal conditions and after immunization with T-dependent antigens
|
neoplasm
|
• between 15 and 20 months, 36-62% developed clonal B cell lymphomas, predominately of splenic orgin, with or without nodal involvement
• tumors displayed a mature B cell phenotype and most were histologically reminiscent of human diffuse large B cell lymphomas and contained clonal karyotypic aberrations
|
hematopoietic system
|
• 42% exhibited abnormal B cell expansions involving predominately the spleen but also the lymph nodes compared to 11% in wild-type and displayed features of benign lymphoproliferative disease
|
|
• about a 30% reduction in the number of total plasmacytoid cells (B220+/- CD138+), mainly due to a decrease in post-CSR plasma cells (IgM-IgD-), while IgM+IgD+ plasma cells were normal
|
|
• 17% displayed a complete effacement of the splenic lymphoid architecture due to the proliferation of large lymphoid cells
|
|
• 17% exhibited a modest splenomegaly at 6 months of age
|
|
• partial effacement of the follicular architecture with the appearance of blast cells
|
|
• nonimmunized mutant mice displayed an increased number of germinal centers, comparable to that observed upon immunization in wild-type mice, and the increase in the number of germinal centers and an increase in the total germinal center area persisted after immunization
|
|
• expanded white pulp composed predominately of B cells, but also included disorganized accumulations of other cell types such as T cells and dendritic cells
|
|
• displayed a small (20-50%) reduction in total serum immunoglobulin levels of all subclasses, except for IgM, both under basal conditions and after immunization with T-dependent antigens
|
growth/size/body
|
• 17% exhibited a modest splenomegaly at 6 months of age
|
cellular
|
• 42% exhibited abnormal B cell expansions involving predominately the spleen but also the lymph nodes compared to 11% in wild-type and displayed features of benign lymphoproliferative disease
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| non-Hodgkin lymphoma | DOID:0060060 |
OMIM:605027 |
J:98937 | |
